Related Experiment Video
Updated: Apr 12, 2026

Determination of Immune Cell Identity and Purity Using Epigenetic-Based Quantitative PCR
Published on: February 19, 2020
Epigenetics meets immune checkpoints
Alessia Covre1, Sandra Coral1, Anna Maria Di Giacomo2
1Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Epigen Therapeutics S.r.l., Pordenone, Italy.
Abstract:
Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availability of new and highly effective immunotherapeutic agents including immune checkpoint(s) blocking monoclonal antibodies, allows us to plan for highly innovative proof-of-principle combination studies that will likely open the path to more effective anticancer therapies.
Insights
Epigenetic drugs can reverse cancer-driving alterations and enhance immune responses. Combining these epigenetic drugs with immunotherapies like immune checkpoint blockers may lead to more effective cancer treatments.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Epigenetic alterations are key drivers in cancer development and progression.
- Pharmacologic interventions can reverse these epigenetic changes.
- Emerging epigenetic drugs exhibit potent immunomodulatory effects.
Purpose of the Study:
- To explore the potential of combining epigenetic drugs with modern immunotherapies.
- To investigate novel combination strategies for enhanced anticancer therapies.
Main Methods:
- Review of current knowledge on epigenetic alterations in cancer.
- Analysis of the immunomodulatory properties of second-generation epigenetic drugs.
- Consideration of the integration of epigenetic drugs with immune checkpoint inhibitors.
Main Results:
- Epigenetic drugs show promise in modulating the tumor immune microenvironment.
- Combination of epigenetic agents and immunotherapies is a feasible strategy.
- This approach has the potential to overcome treatment resistance.
Conclusions:
- Combining epigenetic drugs with immunotherapies represents a promising avenue for novel cancer treatment strategies.
- Further proof-of-principle studies are warranted to validate this therapeutic approach.
- This innovative combination therapy could significantly improve patient outcomes in oncology.
More Related Videos
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
18:08Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
Published on: December 31, 2007
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
Psychoneuroimmunology: Diabetes and Cancer
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...